Messoud Ashina Selected Research

5-HT1B Serotonin Receptor

1/2019	Association Between Sumatriptan Treatment During a Migraine Attack and Central 5-HT1B Receptor Binding.
1/2018	Low 5-HT1B receptor binding in the migraine brain: A PET study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Messoud Ashina Research Topics

Disease

192	Migraine Disorders (Migraine) 05/2024 - 10/2005
97	Headache (Headaches) 04/2024 - 10/2005
33	Pain (Aches) 09/2023 - 04/2002
25	Migraine without Aura (Common Migraine) 05/2024 - 01/2009
25	Epilepsy (Aura) 03/2024 - 09/2008
15	Migraine with Aura (Familial Hemiplegic Migraine) 03/2024 - 09/2008
13	Cluster Headache (Cluster Headaches) 12/2023 - 05/2017
8	Nausea 03/2024 - 12/2010
7	Hypersensitivity (Allergy) 06/2023 - 09/2008
7	Hypoxia (Hypoxemia) 01/2022 - 12/2014
5	Post-Traumatic Headache 03/2024 - 06/2020
4	Brain Concussion (Cerebral Concussion) 04/2024 - 06/2020
4	Flushing 04/2024 - 01/2021
4	Rosacea (Acne Rosacea) 04/2024 - 01/2021
4	Tension-Type Headache (Tension Headache) 01/2021 - 04/2002
3	Respiratory Tract Infections (Respiratory Tract Infection) 03/2024 - 11/2014
3	Constipation 03/2024 - 11/2022
3	Prescription Drug Overuse 01/2023 - 09/2018
3	Ganglion Cysts (Ganglion) 01/2022 - 09/2018
3	Acute Pain 08/2021 - 06/2005
3	Vomiting 07/2021 - 12/2010
3	Photophobia (Light Sensitivity) 07/2021 - 12/2010
3	Hyperacusis (Phonophobia) 07/2021 - 12/2010
3	Headache Disorders (Headache Syndromes) 01/2021 - 04/2002
3	Fatigue 01/2021 - 11/2014
3	Inflammation (Inflammations) 10/2019 - 11/2011
3	Neurogenic Inflammation 06/2013 - 01/2010
2	Urinary Tract Infections (Urinary Tract Infection) 03/2024 - 11/2014
2	Hyperprolactinemia 01/2023 - 01/2023
2	Secondary Headache Disorders 01/2023 - 07/2021
2	COVID-19 01/2023 - 01/2022
2	Nervous System Diseases (Neurological Disorders) 01/2022 - 01/2019
2	Stroke (Strokes) 01/2021 - 01/2021
2	Dizziness (Lightheadedness) 01/2021 - 01/2011

Drug/Important Bio-Agent (IBA)

72	Calcitonin Gene-Related PeptideIBA 04/2024 - 10/2005
38	Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP)IBA 02/2024 - 01/2009
30	Monoclonal AntibodiesIBA 04/2024 - 04/2016
30	erenumabIBA 04/2024 - 04/2016
23	Adenylyl Cyclases (Adenylyl Cyclase)IBA 02/2024 - 06/2010
16	Peptides (Polypeptides)IBA 01/2023 - 01/2010
15	KATP ChannelsIBA 05/2024 - 08/2017
15	Calcitonin Gene-Related Peptide Receptors (Calcitonin-Gene Related Peptide Receptor)IBA 04/2024 - 01/2010
14	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 03/2024 - 12/2010
14	Biomarkers (Surrogate Marker)IBA 06/2023 - 10/2005
14	Sumatriptan (Imigran)FDA LinkGeneric 12/2022 - 04/2011
13	Vasoactive Intestinal Peptide (VIP (Vasoactive Intestinal Peptide))IBA 05/2023 - 10/2013
12	Cromakalim (Levcromakalim)IBA 03/2024 - 01/2019
12	eptinezumabIBA 01/2024 - 11/2014
11	Tryptamines (Triptans)IBA 01/2023 - 04/2009
10	NeuropeptidesIBA 09/2022 - 09/2008
10	Serotonin (5 Hydroxytryptamine)IBA 01/2019 - 01/2003
9	fremanezumabIBA 11/2023 - 01/2019
8	Cilostazol (Pletal)FDA LinkGeneric 04/2024 - 11/2014
8	ProstaglandinsIBA 12/2017 - 01/2003
8	Nitric Oxide (Nitrogen Monoxide)FDA Link 12/2017 - 04/2002
7	Adenosine (Adenocard)FDA LinkGeneric 01/2023 - 01/2003
7	Glutamic Acid (Glutamate)FDA Link 01/2021 - 06/2005
6	PotassiumIBA 12/2023 - 10/2019
6	galcanezumabIBA 06/2022 - 12/2017
6	Nitroglycerin (Dynamite)FDA LinkGeneric 01/2020 - 02/2010
6	salicylhydroxamic acid (SHAM)IBA 01/2020 - 03/2016
5	Type I Pituitary Adenylate Cyclase-Activating Polypeptide ReceptorsIBA 02/2024 - 03/2014
5	Adenosine Triphosphate (ATP)IBA 12/2023 - 01/2003
5	Adenosine Monophosphate (AMP)IBA 12/2023 - 06/2010
5	Protein Isoforms (Isoforms)IBA 01/2023 - 11/2019
5	Glyburide (Glibenclamide)FDA LinkGeneric 01/2023 - 01/2020
5	Histamine (Histamine Dihydrochloride)FDA Link 01/2022 - 01/2003
5	Vasodilator Agents (Vasodilators)IBA 01/2021 - 01/2011
5	Sildenafil Citrate (Viagra)FDA Link 01/2021 - 06/2018
5	Guanosine Monophosphate (5' Guanylic Acid)IBA 12/2020 - 06/2010
5	Neurotransmitter Agents (Neurotransmitter)IBA 12/2017 - 01/2009
4	atogepantIBA 03/2024 - 01/2023
4	Analgesics (Analgesic Drugs)IBA 02/2023 - 04/2002
4	lasmiditanIBA 01/2023 - 04/2019
4	CalciumIBA 11/2022 - 01/2020
4	Type A Botulinum Toxins (Botox)FDA Link 01/2022 - 06/2011
4	Carbon MonoxideIBA 01/2022 - 12/2014
4	Nitric Oxide Synthase (NO Synthase)IBA 01/2017 - 04/2002
3	Purinergic P1 Receptor AntagonistsIBA 01/2023 - 01/2022
3	Purinergic P1 Receptors (Adenosine Receptor)IBA 01/2023 - 01/2022
3	Caffeine (No Doz)FDA LinkGeneric 01/2023 - 01/2022
3	BMS204352IBA 11/2022 - 10/2020
3	Protons (Proton)IBA 01/2021 - 01/2020
3	telcagepantIBA 01/2020 - 12/2010
3	AntibodiesIBA 01/2019 - 11/2017
3	Natriuretic PeptidesIBA 01/2019 - 06/2014
3	Prostaglandins EIBA 08/2012 - 01/2003
3	Epoprostenol (Prostacyclin)FDA LinkGeneric 11/2011 - 09/2008
2	rimegepant sulfateIBA 01/2024 - 04/2019
2	ubrogepantIBA 01/2024 - 04/2019
2	Potassium Channels (Potassium Channel)IBA 12/2023 - 10/2021
2	ProlactinIBA 01/2023 - 01/2023
2	Lactic Acid (Lactate)FDA LinkGeneric 01/2022 - 03/2016
2	Hormones (Hormone)IBA 01/2022 - 04/2021
2	Tryptases (Tryptase)IBA 01/2022 - 01/2019

Therapy/Procedure

30	Therapeutics 03/2024 - 01/2010
22	Intravenous Infusions 03/2024 - 10/2010
3	Subcutaneous Injections 01/2024 - 01/2019
3	Punctures 10/2020 - 01/2017
2	Drug Therapy (Chemotherapy) 01/2024 - 12/2003